Icape Holding S.A. engages in the manufacture, distribution, and sale of printed circuit boards (PCBs) and customized technical parts worldwide. The company offers PCBs, including high-density interconnect, rigid-flex, aluminum, semi-flex. Flex, back panel, heavy copper, multilayer, radio frequency/microwave, double-sided, single-sided, and IC substrate; and electronic parts, such as cables and connectors, adapters, transformers and coils, keyboards and keypads, batteries, displays, plastic and silicone, metal, and remotes. It also provides design-engineering, prototyping, sourcing and production, quality assurance, and laboratory testing services, as well as supply chain and customer care solutions. The company serves the automotive, medical, industrial, consumer and multimedia, aerospace, metering, power/energy, telecom, railway, internet of things (IoT), and lighting industries. Icape Holding S.A. was founded in 1999 and is based in Fontenay-aux-Roses, France.…
Graphique des rendements saisonniers Icape Holding S.A. (Z8J.SG)
Icape Holding (EPA: ALICA) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Electronic Components industry, part of the Technology sector, and reports about 665 employees.
The shares were at 9.420 EUR on 20 November 2026, up 39.6% over 52 weeks. Its 52-week range is 3.560 EUR to 9.940 EUR: the price is 5.2% below the high and 164.6% above the low.
At a market capitalisation of 74.41M EUR, it trades at 16.5 times trailing earnings and 7.5 times forward earnings. The median trailing P/E of its 19 largest Electronic Components peers is 23.7, a discount of 30% for ALICA. It pays a dividend yielding 0.96% (it pays out 21% of its earnings), against a median of 0.81% among the dividend payers in that peer group.
Icape Holding reports return on equity of -1.4%, an operating margin of 2.7% and revenue up 11.1% year over year.
Its debt exceeds its cash by 34.39M EUR, a debt-to-equity ratio of 2.06. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 10.25 EUR is 8.8% above the current price. The next earnings report is expected on 25 March 2027.